Bank of America
NRIX icon

Bank of America’s Nurix Therapeutics NRIX Stock Holding History

Bank of America’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Buy
802,153
+65,595
+9% +$1.09M ﹤0.01% 2787
2025
Q4 		$14M Buy
736,558
+255,504
+53% +$3.67M ﹤0.01% 2581
2025
Q3 		$4.44M Buy
481,054
+153,843
+47% +$1.6M ﹤0.01% 4128
2025
Q2 		$3.73M Sell
327,211
-87,975
-21% -$951K ﹤0.01% 4180
2025
Q1 		$4.93M Buy
415,186
+264,251
+175% +$4.42M ﹤0.01% 3817
2024
Q4 		$2.84M Buy
150,935
+12,811
+9% +$294K ﹤0.01% 4132
2024
Q3 		$3.1M Sell
138,124
-83,203
-38% -$1.88M ﹤0.01% 4186
2024
Q2 		$4.62M Buy
221,327
+124,151
+128% +$1.93M ﹤0.01% 3685
2024
Q1 		$1.43M Buy
97,176
+78,240
+413% +$842K ﹤0.01% 4686
2023
Q4 		$195K Sell
18,936
-527,514
-97% -$3.62M ﹤0.01% 6081
2023
Q3 		$4.3M Sell
546,450
-41,575
-7% -$380K ﹤0.01% 3544
2023
Q2 		$5.87M Sell
588,025
-43,179
-7% -$440K ﹤0.01% 3241
2023
Q1 		$5.61M Sell
631,204
-90,335
-13% -$941K ﹤0.01% 3430
2022
Q4 		$7.92M Buy
721,539
+591,198
+454% +$7.13M ﹤0.01% 2908
2022
Q3 		$1.7M Buy
130,341
+42,527
+48% +$673K ﹤0.01% 4429
2022
Q2 		$1.11M Buy
87,814
+35,264
+67% +$400K ﹤0.01% 4822
2022
Q1 		$736K Sell
52,550
-35,965
-41% -$638K ﹤0.01% 5510
2021
Q4 		$2.56M Buy
88,515
+13,443
+18% +$408K ﹤0.01% 4312
2021
Q3 		$2.25M Buy
75,072
+47,163
+169% +$1.46M ﹤0.01% 4333
2021
Q2 		$740K Sell
27,909
-3,395
-11% -$99.7K ﹤0.01% 5143
2021
Q1 		$973K Buy
31,304
+24,047
+331% +$910K ﹤0.01% 4848
2020
Q4 		$239K Sell
7,257
-1,262
-15% -$41.8K ﹤0.01% 5486
2020
Q3 		$298K Buy
+8,519
New +$215K ﹤0.01% 5057

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bank of America's NRIX Position: Q1 2026 in Review

Bank of America increased its Nurix Therapeutics (NRIX) stake by 8.9% in Q1 2026, buying an estimated $1.09M and bringing the position to 802,153 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2787.

Bank of America first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $14M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Bank of America held 802,153 shares of Nurix Therapeutics worth $12.4M as of Q1 2026.
  • Bank of America bought 65,595 Nurix Therapeutics shares in Q1 2026, an estimated $1.09M.
  • Nurix Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2787 holding.
  • Bank of America first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Bank of America's Nurix Therapeutics position peaked at $14M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.